Momelotinib (Ojjaara)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 02:44, 2 December 2016 by Dryang (talk | contribs) (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm")
Jump to navigation Jump to search

Mechanism of action

JAK1/2 inhibitor

Preliminary data

Myelofibrosis

  1. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7. Epub 2013 Mar 5. PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Momelotinib_(Ojjaara)&oldid=12556"